Q32 Bio Spotlights Bempikibart AA Data Ahead, Sharpens Focus After Asset Sale at Oppenheimer Confab [Yahoo! Finance]
Q32 Bio Inc. (QTTB)
Company Research
Source: Yahoo! Finance
A of the SIGNAL-AA Phase IIa showed statistically significant SALT reductions and apparent durability after dosing cessation, with responses in hard-to-treat patients and a safety profile management says is favorable versus JAK inhibitors. Part B has enrolled 33 patients with operational and eligibility changes (central review, shorter episode duration ~2 years) using a 200 mg regimen, and the company expects top-line data at mid-2026 with remission follow-up to week 52; management is targeting a mid-20s SALT20 as a Phase III gating point. Q32 sharpened its focus on bempikibart after selling ADX-097 to Akebia for $12 million upfront/near-term milestones and potential total consideration of up to ~$592 million plus royalties. Interested in Q32 Bio Inc.? Here are five stocks we like better. Executives from Q32 Bio (NASDAQ:QTTB) detailed progress on the company's lead program, bempikibart, during a discussion at Oppenheimer's 36th Annual Life Science Conference, emphasizing upcom
Show less
Read more
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio (QTTB) is now covered by HC Wainwright. They set a "buy" rating and a $13.00 price target on the stock.MarketBeat
- Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferencePR Newswire
- Q32 Bio Announces $10.5 Million Registered Direct OfferingPR Newswire
- Q32 Bio (NASDAQ:QTTB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
QTTB
Earnings
- 3/11/25 - Beat
QTTB
Sec Filings
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- QTTB's page on the SEC website